Xylem Inc. (LON:0M29)

Achilles Therapeutics Statistics

Total Valuation

Xylem has a market cap or net worth of GBP 26.28 billion. The enterprise value is 27.17 billion.

Market Cap	26.28B
Enterprise Value	27.17B

Important Dates

The last earnings date was Thursday, July 31, 2025.

Earnings Date	Jul 31, 2025
Ex-Dividend Date	May 29, 2025

Share Statistics

Current Share Class	243.41M
Shares Outstanding	n/a
Shares Change (YoY)	+0.39%
Shares Change (QoQ)	+0.05%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	241.78M

Valuation Ratios

The trailing PE ratio is 38.39 and the forward PE ratio is 28.11.

PE Ratio	38.39
Forward PE	28.11
PS Ratio	4.12
PB Ratio	3.18
P/TBV Ratio	74.55
P/FCF Ratio	42.66
P/OCF Ratio	29.42
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 18.78, with an EV/FCF ratio of 44.11.

EV / Earnings	39.69
EV / Sales	4.14
EV / EBITDA	18.78
EV / EBIT	30.00
EV / FCF	44.11

Financial Position

The company has a current ratio of 1.90, with a Debt / Equity ratio of 0.19.

Current Ratio	1.90
Quick Ratio	1.31
Debt / Equity	0.19
Debt / EBITDA	1.10
Debt / FCF	2.52
Interest Coverage	33.58

Financial Efficiency

Return on equity (ROE) is 8.63% and return on invested capital (ROIC) is 5.84%.

Return on Equity (ROE)	8.63%
Return on Assets (ROA)	4.59%
Return on Invested Capital (ROIC)	5.84%
Return on Capital Employed (ROCE)	8.12%
Revenue Per Employee	277,045
Profits Per Employee	29,767
Employee Count	23,000
Asset Turnover	0.53
Inventory Turnover	5.10

Taxes

In the past 12 months, Xylem has paid 164.96 million in taxes.

Income Tax	164.96M
Effective Tax Rate	19.48%

Stock Price Statistics

The stock price has increased by +11.11% in the last 52 weeks. The beta is 1.12, so Xylem's price volatility has been higher than the market average.

Beta (5Y)	1.12
52-Week Price Change	+11.11%
50-Day Moving Average	129.99
200-Day Moving Average	124.70
Relative Strength Index (RSI)	71.91
Average Volume (20 Days)	2,714

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	1.77

Income Statement

In the last 12 months, Xylem had revenue of GBP 6.37 billion and earned 684.65 million in profits. Earnings per share was 2.80.

Revenue	6.37B
Gross Profit	2.41B
Operating Income	882.45M
Pretax Income	846.68M
Net Income	684.65M
EBITDA	1.30B
EBIT	882.45M
Earnings Per Share (EPS)	2.80

Balance Sheet

The company has 853.98 million in cash and 1.55 billion in debt, giving a net cash position of -696.32 million.

Cash & Cash Equivalents	853.98M
Total Debt	1.55B
Net Cash	-696.32M
Net Cash Per Share	n/a
Equity (Book Value)	8.25B
Book Value Per Share	33.21
Working Capital	1.51B

Cash Flow

In the last 12 months, operating cash flow was 893.40 million and capital expenditures -277.36 million, giving a free cash flow of 616.04 million.

Operating Cash Flow	893.40M
Capital Expenditures	-277.36M
Free Cash Flow	616.04M
FCF Per Share	n/a

Margins

Gross margin is 37.81%, with operating and profit margins of 13.85% and 10.74%.

Gross Margin	37.81%
Operating Margin	13.85%
Pretax Margin	13.29%
Profit Margin	10.74%
EBITDA Margin	20.41%
EBIT Margin	13.85%
FCF Margin	9.67%

Dividends & Yields

This stock pays an annual dividend of 1.17, which amounts to a dividend yield of 0.82%.

Dividend Per Share	1.17
Dividend Yield	0.82%
Dividend Growth (YoY)	7.66%
Years of Dividend Growth	7
Payout Ratio	39.55%
Buyback Yield	-0.39%
Shareholder Yield	0.42%
Earnings Yield	2.61%
FCF Yield	2.34%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Xylem has an Altman Z-Score of 4.29 and a Piotroski F-Score of 8.

Altman Z-Score	4.29
Piotroski F-Score	8